News Release

Study illuminates sugar’s role in common kidney disease

In a novel lab environment using mini kidney structures, drugs blocked the swelling of tubes that is seen with polycystic kidney disease

Peer-Reviewed Publication

University of Washington School of Medicine/UW Medicine

1-PKD cyst expansion

image: An illustration shows fluid absorption and cyst expansion in kidney organoids infected with polycystic kidney disease (PKD). The outward-facing proximal tubular epithelial cells (green) absorb fluid, generating pressure that causes expansion and stretching of the epithelium, creating cysts. It is unclear why normal epithelial cells resist cyst formation. view more 

Credit: Benjamin Freedman Lab / University of Washington School of Medicine

A study of kidney organoids in a novel lab environment might have downstream implications for the treatment of polycystic kidney disease (PKD), an incurable condition that affects more than 12 million people worldwide.

One key discovery of the study: Sugar appears to play a role in the formation of fluid-filled cysts that are PKD’s hallmark. In people, these cysts grow big enough to impair kidney function and ultimately cause the organs to fail, necessitating dialysis therapy or transplant.

The findings were published in Nature Communications. The co-lead authors are Sienna Li and Ramila Gulieva, research scientists in the lab of Benjamin Freedman, a nephrology investigator at the University of Washington School of Medicine.

“Sugar uptake is something that kidneys do all the time,” said Freedman, a co-senior author. “We found that increasing the levels of sugar in the dish cultures caused cysts to swell. And when we employed drugs known to block sugar absorption in the kidneys, it blocked this swelling. But I think it relates less to blood sugar level and more to how kidney cells take in sugar — which in this process seemed to go rogue and give rise to cysts.”

For years Freedman has studied PKD in organoids grown from pluripotent stem cells.  Organoids resemble miniature kidneys: They contain filtering cells connected to tubes and can respond to infection and therapeutics in ways that parallel the responses of kidneys in people.

Although his team can grow organoids that give rise to PKD cysts, the mechanisms of those cysts’ formation are not yet understood. In this investigation, the researchers focused on how the flow of fluid within the kidney contributes to PKD.

To do so, they invented a new tool that merged a kidney organoid with a microfluidic chip. This allowed a combination of water, sugar, amino acids and other nutrients to flow over organoids that had been gene-edited to mimic PKD. 

“We were expecting the PKD cysts in the organoids to get worse under flow because the disease is associated with the physiological flow rates that we were exploring,” Freedman explained. “The surprising part was that the process of cyst-swelling involved absorption: the intake of fluid inward through cells from outside the cyst. That’s the opposite of what is commonly thought, which is that cysts form by pushing fluid outward through cells. It’s a whole new way of thinking about cyst formation.”

In the chips, the researchers observed that the cells lining the walls of the PKD cysts faced outward as they stretched and swelled, such that the tops of the cells were on the outside of the cysts. This inverted arrangement — these cells would be facing inward in living kidneys — suggests that cysts grow by pulling in sugar-rich fluid, not by secreting the liquid.

The observation gives researchers more information about how cysts form in organoids, a finding that will have to be tested further in vivo. As well, the fact that sugar levels drive cyst development points to new potential therapeutic options.

“The results of the experiment are significant because there is a whole class of molecules that block sugar uptake in the kidneys and are attractive therapeutics for a number of conditions,” Freedman said. “They haven’t been tested yet, but we view this as a proof-of-concept that these drugs could potentially help PKD patients.”

Dr. Jonathan Himmelfarb, professor of medicine (nephrology) at the UW School of Medicine, was a co-senior author of the paper.

The work was supported by the National Institutes of Health (UG3TR002158, UG3TR003288, UG3TR000504, K01DK102826, R01DK117914, U01DK127553, UC2DK126006, U01HL152401), a Novo Nordisk-sponsored research award, a gift from the Northwest Kidney Centers to the Kidney Research Institute, the Lara Nowak Macklin Research Fund, a gift from the Mount Baker Foundation, and startup funds from the University of Washington.

A competing interests statement can be found in the Nature Communications paper or may be obtained by contacting

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.